Teladoc Health, Inc.
Reads like this one publish minutes after the filing lands on EDGAR. Get them as JSON over the API or inside your AI agent over MCP.
Teladoc Health (TDOC) is set to report Q3 earnings, with analysts expecting a 6.1% year-on-year revenue decline. The company missed revenue expectations last quarter, reporting $606.9 million, down 4% year on year. Analysts have generally reconfirmed their estimates, and Teladoc's stock is up 6.1% over the last month, with an average price target of $7.47.
Newfoundland and Labrador spent $32.1 million on Teladoc's virtual health services over 2.5 years. The province extended its contract with Teladoc, which now operates in 10 emergency rooms and 4 urgent care centers. The Newfoundland and Labrador Medical Association criticizes the reliance on virtual care due to doctor shortages. Teladoc Health is headquartered in New York City.
Teladoc Health (TDOC) introduced SoloVitals and SoloScribe, AI tools for virtual visits. The stock is down 11.46% in 30 days and 39.63% in 90 days, with a 1-year return decline of 38.83%. Analysts suggest it may be 63% undervalued, citing a fair value of $15.00. The company has $750M in cash and generates $130M-$170M in annual free cash flow, but faces risks from competitors and pricing pressures.
Over the past 7 days, AlphAI's AI scored 1 news story mentioning TDOC (Teladoc Health, Inc.). Coverage has skewed bearish: 0 bullish, 0 neutral, and 1 bearish.
Recent TDOC coverage spans financial news, earnings and corporate actions.
In the last 30 days, TDOC insiders filed 1 SEC Form 4 transaction — no purchases and 1 sale ($4K). The most active reporter was Catapano Joseph Ronald, Chief Accounting Officer, with 1 filing.
Teladoc is likely to face selling pressure as investors anticipate continued revenue weakness and below‑expectation guidance.
The contract expansion may raise scrutiny over Teladoc's public‑sector growth and could pressure the stock if investors view the spending as a sign of systemic healthcare shortages.
The AI tool launch could modestly improve Teladoc's service offering, but the stock remains pressured by recent price declines.
The new AI capabilities could boost enterprise adoption and future ARR, but immediate revenue impact is uncertain.
The resignation adds to recent leadership churn and weak guidance, likely prompting further selling.
AlphAI scores every news story that mentions TDOC with an AI model for sentiment and relevance, and aggregates insider trades from Teladoc Health, Inc.'s SEC EDGAR Form 4 filings. Figures refresh continuously.
Teladoc Health (TDOC) is set to report Q3 earnings, with analysts expecting a 6.1% year-on-year revenue decline. The company missed revenue expectations last quarter, reporting $606.9 million, down 4% year on year. Analysts have generally reconfirmed their estimates, and Teladoc's stock is up 6.1% over the last month, with an average price target of $7.47.
2 min readNewfoundland and Labrador spent $32.1 million on Teladoc's virtual health services over 2.5 years. The province extended its contract with Teladoc, which now operates in 10 emergency rooms and 4 urgent care centers. The Newfoundland and Labrador Medical Association criticizes the reliance on virtual care due to doctor shortages. Teladoc Health is headquartered in New York City.
2 min readTeladoc Health (TDOC) introduced SoloVitals and SoloScribe, AI tools for virtual visits. The stock is down 11.46% in 30 days and 39.63% in 90 days, with a 1-year return decline of 38.83%. Analysts suggest it may be 63% undervalued, citing a fair value of $15.00. The company has $750M in cash and generates $130M-$170M in annual free cash flow, but faces risks from competitors and pricing pressures.
2 min readTeladoc Health (TDOC) launched AI features SoloVitals and SoloScribe for its Solo platform. SoloScribe is available now, while SoloVitals is in private preview with a general release expected in December 2026. The features aim to enhance hospital penetration and AI integration.
1 min readTeladoc (TDOC) shares fell 2.3% to $5.95 amid leadership transition concerns. The company's CLO resigned, raising governance questions. The stock has declined since Q2 revenue missed expectations and guidance was cut. Analysts have lowered price targets, and institutional selling has increased. The broader market's decline added pressure. TDOC trades near its 52-week low of $4.40.
2 min readTeladoc Health, Inc. (TDOC) filed an SEC Form 8-K — Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers. Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers. On September 24, 2026, Mr. Adam C. Vandervoort, Chief Legal Officer and Secretary of Teladoc Health, Inc. (the "Company"),
1 min readDIVITA CHARLES III (CHIEF EXECUTIVE OFFICER) sold 17,805 shares of Teladoc Health, Inc. (TDOC) at $6.10 ($0.11M total) on 2026-09-11.
1 min readTeladoc Health (TDOC) and Recursion Pharmaceuticals (RXRX) face significant challenges. Teladoc's revenue declined 4% YoY to $606.9M, with BetterHelp's revenue and users dropping 12% and 11% YoY, respectively. Recursion, an AI-driven biotech, lacks approved products and has seen its stock fall 21% over the past year. Both companies show dim prospects, according to the analysis.
2 min readTeladoc Health's (TDOC) Integrated Care segment is driving profitability, generating $394.3M in Q2 revenue and $65.2M in adjusted EBITDA. The segment's focus on chronic care and enterprise contracts positions it for growth, while Teladoc One, launching in 2027, could further boost earnings. TDOC shares have gained 18.5% over six months, trading at a forward P/S ratio of 0.47X.
2 min readTeladoc Health granted new CFO Michael Grasher 239,616 restricted stock units and performance stock units, with vesting tied to service and financial targets. The performance stock units are linked to 2026 EBITDA and 2026-2028 revenue growth.
1 min read
